Braveheart Inv Regulatory News (BRH)

19 September 2019

Braveheart Investment Group plc

("Braveheart" or the "Group")

Results of customer trials by Pharm2Farm Limited

Braveheart Investment Group plc (AIM: BRH), the fund management and strategic investment group, is pleased to report that Pharm2Farm Limited ("Pharm2Farm"), an investee company in which Braveheart has a 33 per cent. interest has completed product trials with Griin Agriculture Co. ("Griin") in Korea. In these trials, Griin used its proprietary vertical hydroponic system, designed to grow the herb basil intensively in indoor, inner city locations.

The Korean team compared plants grown indoors, under controlled conditions. Plants grew much faster and had an improved taste when Pharm2Farm nanoparticles were added to their nutrient feeds.

Over a 20 day harvesting period, the treated plants produced 33 per cent. more leaves with more intense taste than the untreated plants. Griin sells the basil to local shops and restaurants, who value the high quality, freshness, low miles and eco-friendly nature. Customers appreciate that fresh vegetables taste better and research shows that some produce loses more than 50 per cent. of its nutrition within days of harvesting.

Trace minerals, such as iron, copper, silicon, are essential for healthy plant growth, but historically they have been difficult to incorporate into a fertilizer in a form which can be readily taken up by plants.

Pharm2Farm's coated nanoparticle technology, has been demonstrated to dramatically increase the bioavailability of trace minerals in plant feeds applicable to all areas of the farming market.

For further information:

About RNS Reach Announcements

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.